A mutation in the 5′ untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency

Journal of International Medical Research

Volumn 35, Issue 4, 2007, Pages 564-573

  Wang, J ^a,b   Lu, C ^b   Min, D ^c   Wang, Z ^b   Ma, X ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

^c The Anhui Province Tumour Hospital   (China)

Author keywords

BRCA1; Breast cancer; Gene expression; Gene mutations; Gene sequencing; Infilitrating ductal carcinoma; Translational control

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CHINESE DRUG; LUCIFERASE; MESSENGER RNA; BRCA1 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; CHINESE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLATION REGULATION; TUMOR RECURRENCE; WILD TYPE; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PAGET NIPPLE DISEASE; PATHOLOGY; PROTEIN SYNTHESIS; TUMOR SUPPRESSOR GENE;

5' UNTRANSLATED REGIONS; ADULT; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; FEMALE; GENES, BRCA1; HUMANS; MIDDLE AGED; MUTATION; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 34547885781     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500417     Document Type: Article

References (29)

1. Seo JH, Cho DY, Ahn SH, et al: BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer. Hum Mutat 2004; 24: 350-357.
2. Hall JM, Lee MK, Newman B, et al: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1689.
3. Szabo CI, King MC: Inherited breast and ovarian cancer. Hum Mol Genet 1995; 4(Rev Iss 1): 1811-1817.
4. Merajver SD, Pham TM, Caduff RF, et al: Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995; 9: 439-443.
5. Thompson ME, Jensen RA, Obermiller PS, et al: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9: 444-450.
6. Pickering BM, Willis AE: The implications of structured 5′ untranslated regions on translation and disease. Semin Cell Dev Biol 2005; 16: 39-47.
7. Kozak M: Initiation of translation in prokaryotes and eukaryotes. Gene 1999; 234: 187-208.
8. Kozak M: An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125-8148.
9. Zheng L, Pan H, Li S, et al: Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 2000; 6: 757-768.
10. Levy-Lahad E, Wildin RS: Neonatal diabetes mellitus, enteropathy, thrombocytopenia, and endocrinopathy: further evidence for an X-linked lethal syndrome. J Pediatr 2001; 138: 577-580.
11. Conne B, Stutz A, Vassalli JD: The 3′ untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 2000; 6: 637-641.
12. Cazzola M, Skoda RC: Translational pathophysiology: a novel molecular mechanism of human disease. Blood 2000; 95: 3280-3288.
13. Osada Y, Saito R, Tomita M: Comparative analysis of base correlations in 5′ untranslated regions of various species. Gene 2006; 375: 80-86.
14. Taylor J, Lymboura M, Pace PE, et al: An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers, Int J Cancer 1998; 79: 334-342.
15. Signori E, Bagni C, Papa S, et al: A somatic mutation in the 5′UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency. Oncogene 2001; 20: 4596-4600.
16. Liu J, Prolla G, Rostagno A, et al: Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa). Oncogene 2000; 19: 2767-2773.
17. Sambrook J, Russell DW: Preparation and analysis of eukaryotic genomic DNA: DNA extraction from paraffin blocks. In: Molecular Cloning - a Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2002; vol 3, chapter 6.27.
18. Gross E, Arnold N, Pfeifer K, et al: Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum Mutat 2000; 16: 345-353.
19. Ford D, Easton DE Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
20. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695.
21. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
22. Yin Y, Stephen CW, Luciani MG, et al: p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 2002; 4: 462-467.
23. Landers JE, Cassel SL, George DL: Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997; 57: 3562-3568.
24. Capoulade C, Mir LM, carlier K, et al: Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood 2001; 97: 1043-1049.
25. Capoulade C, Bressac-de Paillerets B, Lefrere I, et al: Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998; 16: 1603-1610.
26. Yoshikawa K, Honda K, Inamoto T, et al: Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 1999; 5: 1249-1261.
27. Jarvis EM, Kirk JA, Clarke CL: Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 1998; 101: 109-115.
28. Holt JT, Thompson ME, Szabo C, et al: Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996; 12: 298-302.
29. Sobczak K, Krzyzosiak WJ: Structural determinants of BRCA1 translational regulation. J Biol Chem 2002; 277: 17349-17358.